Own Immutep shares? Here are 3 takeaways from the company's investor update

Investors were mute to the update.

| More on:
A businessman presents a company annual report in front of a group seated at a table

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Immutep shares have been heavily sold in 2022 along with the wider sector 
  • Despite this, it continues to post updates regarding its etfi candidate, including its most recent presentation at the ASCO 2022 Special Edition 
  • Immutep shares have tumbled more than 40% into the red these past 12 months 

Shares of biotech Immutep Ltd (ASX: IMM) have had a hard time this year to date, down 35% since trading resumed in January.

At the time of writing, investors are paying 30.5 cents apiece for the Immutep share price.

Earlier this month, Immutep released the slide deck of its presentation at the American Society of Clinical Oncology (ASCO) 2022 Special Edition. Let's take a closer look.

Immutep's biotech assets on full display

ASCO is the world's biggest clinical cancer research conference, Immutep says. This year the company announced clinical results from Part A of its Phase II TACTI-002 trial.

The trial is investigating Immutep's lead drug candidate, eftilagimod alpha – also known as efti – when given in combination with pembrolizumab, known as Keytruda.

"Importantly, the trial met its primary objective, delivering promising efficacy in this large indication and warranting late-stage clinical development of efti in this indication," Immutep posted in its slide deck.

"By benchmarking our TACTI-002 results against other approved treatments, the efti and pembrolizumab combination compares favourably," it added.

Additionally, due to the positive data from efti presented at ASCO and other conferences, Immutep has been approached for potential new investigator-initiated trials as well as other potential collaborations for efti in various indications and combinations which we are currently assessing.

Furthermore, the Phase II TACTI-002 trial has been selected for readouts at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022).

The conference is taking place both in-person and online from 6-9 August 2022 in Vienna, Austria.

Despite continued updates with its etfi label, Immutep shares have tumbled more than 40% into the red these past 12 months.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »